If you’ve been following Georgia’s cannabis saga for any length of time then you know the pattern already: a promising bill gets introduced, legislators debate it endlessly, something slightly better than nothing eventually passes, and patients are still left trying to figure out how to access medicine that’s technically legal for them to possess but impossible to legally obtain.
Well, I’m hesitant to say it but it appears that the Putting Patients First Act may have just broken that cycle.
On March 23, 2026, Georgia’s General Assembly sent Senate Bill 220 — officially dubbed the “Putting Georgia’s Patients First Act” — to Governor Brian Kemp’s desk after both chambers gave it final approval.
The House passed it 144-21 and the Senate concurred 38-14, a notably bipartisan outcome for a state that has historically moved at a glacial pace on cannabis reform.
What SB 220 Does for Medical Cannabis in GA
So, what would SB220 do for Georgia’s lackluster medical cannabis program? From renaming the entire program to eliminating the low THC cap, this bill truly aims to do what it claims and put patients first.
A Name Change That Actually Matters
First and most symbolically, the bill renames Georgia’s program. Out goes the clunky “low-THC oil” designation; in comes “medical cannabis” — the term every other state uses and what patients and providers have been calling it all along.
Rep. Mark Newton (R-Augusta), who sponsors the bill in the House, made a point of this before the floor vote: “the old name was something most people — maybe even some lawmakers in the room — didn’t really understand. Calling it what it is matters for recognition, for access, and frankly for getting almost anyone to even acknowledge that Georgia has a functioning program at all.”
Beyond the rebrand, the numerous changes this bill aims to make are significant – especially in a state with such a restrictive program that many don’t know it exists.
Key Changes SB220 Would Make
- The 5% THC cap is gone. Patients will now be able to possess up to 12,000 milligrams of THC at any given time, with individual product packages capped at 1,200 milligrams. This opens the door to a much wider range of products and potencies than the current program allowed.
- Vaporization is now permitted but will be restricted to those 21 and older and limited to private settings — no public use — but for patients who need relief faster than an oil tincture delivers it, this is a meaningful shift.
- New qualifying conditions are added including lupus, severe arthritis, and severe insomnia.
- The “severe” and “end-stage” requirements are out – in some cases, anyway. Conditions like cancer, multiple sclerosis, and Parkinson’s disease no longer require a patient to be in a severe or end-stage status to qualify. (That had always been a particularly cruel bit of fine print, and it’s long past time it came out.)
- Patient registry cards are now valid for five years. Previously, patients had to navigate annual renewals regardless of their condition.
- Patients with incurable or irreversible conditions won’t have to re-certify annually. For people managing permanent conditions, removing that bureaucratic hurdle is a genuine quality-of-life improvement.
A note on what’s still missing: dried flower and pre-rolls remain prohibited under SB 220, and most edibles like cookies and candies are still out (though the bill’s language around products like gummies is ambiguous enough that it’ll likely need clarification as implementation begins).
It’s not a perfect bill. Not by any means. But it’s the most meaningful expansion Georgia has seen since the program began.
Changes to Medical Cannabis Access in GA Are Long Overdue
For those of you who are newer to my news coverage, know this isn’t the first time I’ve put the spotlight on GA for their less than impressive effort to provide safe access to medical cannabis. I’ve been writing about this state’s cannabis struggles for nearly a decade, and the frustration has been real, and honestly, infuriating since I personally know people in the state who could benefit from a properly implemented program.
Years of Promised Access, No Real Delivery
Back in 2017, I covered the Georgia Senate’s final approval of a medical marijuana expansion bill that added conditions like autism, AIDS/HIV, Tourette’s syndrome, and Alzheimer’s to the qualifying list. At the time I noted that even with that progress the law still gave patients no legal way to actually access the medicine they were now technically permitted to possess.
That tension — legal possession, zero legal access — has defined Georgia’s program for years and left patients in an impossible situation in the process.
By 2019, I was writing about a production bill making its way through the House that would have allowed 60 dispensaries and finally given patients a real path to obtaining their medicine legally. That legislation eventually formed the foundation for the in-state production system that exists today — but progress continued to be agonizingly slow, and the program remained severely limited.
The Brills: What Happens When the Law Fails Patients
And in between all of that, there were families like the Brills.
In 2018 I wrote a story on The Marijuana Times about Suzeanna and Matthew Brill, a couple from Georgia who made the desperate decision to treat their 15-year-old son David’s severe seizures with cannabis after every pharmaceutical option had failed them.
CBD oil — technically legal in Georgia for epilepsy — hadn’t worked. They were at a loss for options, watching their son suffer. David was having seizures constantly. So, they got cannabis flower, administered it carefully, and watched as their son went 71 seizure-free days for the first time in his life.
Then a therapist reported them to Georgia’s Division of Family and Children Services.
The parents were arrested and jailed for six days. David was removed from their custody and placed in a group home 60 miles away. The day he was taken, he suffered what his mother described as “the worst seizure of his life,” flatlining 15 times in the hospital according to family accounts.
The state had just forced a critically ill teenager to stop the only treatment that had ever worked for him — and then locked up his parents for doing what any good parent would, anything they could that might help.
Conflicting Feelings and a Complicated Resolution
The ACLU of Georgia eventually filed an amicus brief on the family’s behalf, and a Twiggs County Juvenile Court judge issued a protective order reuniting David with his parents in July 2018. The criminal reckless conduct charges were still pending, but the judge indicated they could ultimately be dismissed if the family cooperated with DFCS terms. David was set to be prescribed Epidiolex — the FDA-approved cannabis-derived treatment — though obtaining it in Georgia remained its own bureaucratic obstacle course.
The Brills’ story was heartbreaking precisely because it illustrated what happens when a state gives patients permission to possess medicine that it refuses to let them legally access or use in the most effective form available. And for years after that — even as other states moved forward — Georgia kept right on doing exactly that.
The Hemp Market Workaround — and Why It’s Not a Real Solution
While the medical program has been crawling forward, a lot of Georgia residents who actually need cannabis relief have been quietly navigating a separate and significantly messier alternative: the legal hemp market.
The De Facto Cannabis Market Georgia Actually Built
After the 2018 federal Farm Bill opened the door nationally, Georgia eventually followed — and for a few years, that meant access to a surprisingly wide range of cannabinoids through vape shops, smoke shops, and wellness stores across the state.
THC-A, Delta-8 THC, Delta-10, HHC, THCP, and similar hemp-derived compounds filled a gap that the medical program simply couldn’t. You didn’t need a doctor’s card, you didn’t need to register with the state, and you could find these products at the corner gas station.
Many people whose conditions would qualify them for the medical program saw the legal hemp market as the obvious solution. Especially for those who couldn’t afford the doctors recommendation, dispensary prices, or who just wanted something that actually worked for them without bureaucratic hoops, the hemp market was the obvious solution.
And to be clear, it still largely is — with some major recent change that might not be in the favor of those seeking medicine over a recreational buzz.
SB 494: Georgia Banned the Natural While Keeping the Synthetic
I was actually staying in Georgia in April 2024 when Governor Kemp did something that still makes my head spin a little: SB 494 effectively banned THCA products while leaving Delta-8, Delta-10, HHC, THCP, and most other chemically converted hemp cannabinoids fully legal.
The bill went into effect October 1, 2024 – and I snagged a ton of deals as shops moved to clear out their shelves of the now illegal product. The legislature even specifically rejected an amendment that would have put those compounds under the same 0.3% threshold as delta-9 THC – they decided only THCA should count toward that cap.
Let that sit for a second.
THCA is tetrahydrocannabinolic acid — the raw, precursor form of THC as it naturally exists in the cannabis plant before it’s heated. It’s cannabis in about as close to its natural state as you can get in a hemp product. But under SB 494, it now counts toward the total delta-9 THC calculation (since heat converts THCA to delta-9), which technically makes it impossible for THCA flower or concentrates to comply with the 0.3% cap.
Hemp flower sales were also banned outright. Meanwhile, Delta-8, Delta-10, HHC, and THCP — all of which are produced through chemical conversion processes applied to CBD, not naturally occurring in meaningful quantities in the hemp plant — remain perfectly legal, with no potency limit, as long as the final product clocks in under 0.3% delta-9 THC.
You can walk into a shop in Georgia and buy a vape cart with enough THCP to level an elephant, but heaven forbid someone sell you a THCA pre-roll.
The regulatory logic here is backwards at best, and most people in the cannabis space know it.
Better CoA Requirements are Beneficial but Still Not Good Enough
SB 494 did introduce some genuinely helpful consumer protections — full panel certificates of analysis are now required for all hemp products. Those CoAs must be updated annually, and potency information must be displayed or accessible via QR code.
That’s real progress from the Wild West days when products had no meaningful testing requirements and CoAs, when they existed at all, were frequently cherry-picked, outdated, or outright sketchy.
If you’ve ever purchased a delta-8 product and tried to locate a legitimate third-party lab report, you know what I’m talking about: the CoA that magically only tests for delta-9 THC and nothing else, the batch number that doesn’t match what’s on the label, the lab with no verifiable accreditation that somehow certifies every single product from the same company…
The new requirements raise the bar, but they don’t necessarily fix the problem. The hemp market still operates largely outside the kind of standardized oversight that a licensed dispensary faces — often less knowledgeable staff, no seed-to-sale tracking, no state-licensed cultivation standards.
Don’t forget the products themselves, particularly the synthetically derived THC analogs, have limited long-term safety data because they simply haven’t been studied the way cannabis has. Consumers are largely trusting that what’s on the label is what’s in the product, and that the chemical processes used to create these compounds are being done cleanly and without harmful residuals.
It’s a Band-Aid solution for a population that has been left without a real one for a long time – and it’s exactly the kind of situation that a well-functioning medical program with licensed dispensaries, regulated products, and trained staff — is supposed to replace.
For patients who have been relying on the hemp market as their only real alternative, a functional medical program with a wider variety of potency options and clinical oversight isn’t just an upgrade — it’s the legitimacy and safety the workaround market was never and will never be able to provide.
In fact, that’s one of the reasons that medical cannabis programs continue to operate even after adult use becomes legal within the state. These are two different markets, with two different consumers, and while there is a lot of crossover, those seeking medical cannabis will always be best advised by a certified and knowledgeable physician or nurse practitioner.
Is SB 220 Enough? Not Really, but It’s Better Than Nothing
Georgia Has the Lowest MMJ Enrollment Rate in the Country
Let me be honest: no, not exactly — but it’s a real step forward in a way Georgia hasn’t managed up to now.
The patient registry numbers alone tell the story of just how restricted the program has been.
As of late 2025, there were roughly 34,500 active patients and 2,200 caregivers registered in the state. Georgia has had the lowest program adoption rate among all 42 states with medical cannabis programs — sitting at around 0.3% of the population.
For comparison, Florida — a state with its own complicated history of restrictive cannabis policy — has about 4% of its population enrolled in its medical program. That’s not an accident. It’s a direct result of a program so narrowly defined, so confusingly named, and so limited in its available products that many qualifying patients simply haven’t engaged with it.
What’s Still Missing
SB 220 addresses some of these issues, but advocates have been honest that this bill reflects what was considered politically achievable right now — not necessarily the full picture of what patients actually need.
The continued prohibition on dried flower is still a meaningful gap – one that will be a deciding factor for many patients who still prefer old fashion flower to a modern vape. It also remains the most accessible and cost-effective form of cannabis for many patients.
That said — listen to the patients who use it like Danielle Rasor. A young mother with multiple sclerosis who shared her story with local Atlanta news during the bill’s coverage, she described the program simply: it’s been a miracle for her family, giving her the energy and quality of life she needs to keep up with her young child and run her business.
Expanding access — even incrementally — means more people like Danielle can find relief without having to relocate to a state where the law makes room for them.
Now It’s Kemp’s Call on Expanding Medical Marijuana Access in GA
Everything rests with Governor Brian Kemp. He can sign SB 220, allow it to become law without his signature, or veto it.
If he signs, Georgia officially becomes the 41st state with a functioning medical cannabis program — one that finally uses the same language, the same standards, and more of the same compassion the most of the country figured out years ago.
There’s been no indication yet of which way Kemp will go. But with a 144-21 House vote and 38-14 Senate support — genuinely bipartisan, genuinely decisive — it would be a difficult veto to defend to the families who have been waiting on this for a very long time.
Have thoughts on SB 220 or where Georgia’s program goes from here? Drop them in the comments below.
Wanna support independent cannabis journalism? Visit All Things Cannabis on Ko-Fi where you can support our work for as little as $1/month, gain access to exclusive content, early-access to posts, books, and more!
